Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli

Sidjabat, Hanna E., Paterson, David L., Qureshi, Zubair A., Adams-Haduch, Jennifer M., O'Keefe, Alexandra, Pascual, Alvaro, Rodríguez-Baño, Jesús and Doi, Yohei (2009) Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli. Clinical Infectious Diseases, 48 6: 739-744. doi:10.1086/597037


Author Sidjabat, Hanna E.
Paterson, David L.
Qureshi, Zubair A.
Adams-Haduch, Jennifer M.
O'Keefe, Alexandra
Pascual, Alvaro
Rodríguez-Baño, Jesús
Doi, Yohei
Title Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli
Formatted title
Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli
Journal name Clinical Infectious Diseases   Check publisher's open access policy
ISSN 1058-4838
1537-6591
Publication date 2009-03-15
Sub-type Article (original research)
DOI 10.1086/597037
Volume 48
Issue 6
Start page 739
End page 744
Total pages 6
Editor Sherwood L. Gorbach
Place of publication Cary, NC, U.S.A.
Publisher Oxford University Press
Collection year 2010
Language eng
Subject C1
920109 Infectious Diseases
110309 Infectious Diseases
Formatted abstract
Background. Knowledge of the clinical features of infections caused by Escherichia coli strains that produce plasmid-mediated AmpC β-lactamase is limited. Of the several groups of plasmid-mediated AmpC β-lactamases, CMY-type β-lactamase is the most common in the United States.

Methods. We prospectively identified patients infected or colonized with E. coli strains that produce CMY-type β-lactamase, and we collected clinical data over a 7-month period. A retrospective cohort study was performed to identify features associated with these cases. Patients with extended-spectrum β-lactamase–producing E. coli were used as a control group. Pulsed-field gel electrophoresis, plasmid analysis, and phylogenetic typing were performed.

Results. Twenty-two patients with infection or colonization due to CMY-type β-lactamase–producing E. coli and 25 patients with infection or colonization due to extended-spectrum β-lactamase–producing E. coli were identified. The demographic characteristics of the patients were similar in both cohorts. Patients with CMY-type β-lactamase–producing E. coli were significantly more likely to have symptomatic infection than were patients with extended-spectrum β-lactamase–producing E. coli (P=.028). The CMY-type β-lactamase was identified as CMY-2 or its variants. Ninety-four percent of the CMY-type β-lactamase–producing isolates belonged to E. coli phylogenetic groups B2 and D, which are associated with virulence. Many of the isolates shared similar plasmid profiles, whereas the pulsed-field gel electrophoresis profiles were diverse. Co-resistance to non–β-lactam antimicrobials was common.

Conclusion. In Pittsburgh, Pennsylvania, CMY-type β-lactamase–producing E. coli strains are almost as common as extended-spectrum β-lactamase–producing E. coli strains, and they cause symptomatic infection in the majority of cases.
Keyword CMY-type beta-lactamases
Escherichia coli (E. coli)
Molecular epidemiology
CMY-type β-lactamases
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
2010 Higher Education Research Data Collection
ERA 2012 Admin Only
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 38 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 39 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 03 Sep 2009, 08:34:19 EST by Mr Andrew Martlew on behalf of UQ Centre for Clinical Research